The biocompatibility of the hydrogels with different concentrations (17.5%, 12.5% and 8%) was tested on L929 mouse fibroblast cells using PrestoBlue™ cell viability assay. The experiment was set up to mimic a real-life skin model by inserting a Transwell™ cell culture insert on top of the cell media to act as a porous barrier between the cells and the hydrogel (Figure ). In addition, a solution of 5 mM GSH was added to the hydrogels to trigger degradation and to allow investigation of the degradation products' cytotoxicity. Figure shows a live/dead assay result in the form of a microscopic fluorescent image recorded for the cells incubated with 17.5% hydrogel after 24 h. Incubated cells were stained with a mixture of calcein-AM and propidium iodide dyes, which differentiated their live or dead state through green and red fluorescence, respectively. The remarkably dominant green color showed that an great majority of the cells remained alive. As for the PrestoBlue™ assay tested on the variable concentrations and degradation products of the hydrogels, cells showed excellent viability after 24 h as well as 96 h, which demonstrated the high biocompatibility of the systems. We envision these hydrogels serving as a delivery platform to ensure the controlled topical transport of active pharmaceutical ingredients. We therefore encapsulated vancomycin in the hydrogel network during hydrogel preparation. Vancomycin is a glycopeptide antibiotic medication used to treat bacterial infections. It is applied intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, and bone and joint infections.